{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T05:03:18Z","timestamp":1780117398007,"version":"3.54.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Santen Pharmaceutical Co., Ltd., Osaka, Japan"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s12325-026-03566-8","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T08:04:34Z","timestamp":1774944274000},"page":"2568-2579","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phase\u00a0III Prospective Randomised Study of Netarsudil and Concomitant Latanoprost Efficacy and Safety for Primary Open-Angle Glaucoma or Ocular Hypertension in Japan: J-ROCKET-2"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6810-0583","authenticated-orcid":false,"given":"Makoto","family":"Aihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"issue":"4","key":"3566_CR1","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1167\/iovs.08-2843","volume":"50","author":"RN Weinreb","year":"2009","unstructured":"Weinreb RN, Kaufman PL. The glaucoma research community and FDA look to the future: a report from the NEI\/FDA CDER Glaucoma Clinical Trial Design and Endpoints Symposium. Invest Ophthalmol Vis Sci. 2009;50(4):1497\u2013505.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"3566_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.4103\/tjo.tjo_63_20","volume":"10","author":"H Jayaram","year":"2020","unstructured":"Jayaram H. Intraocular pressure reduction in glaucoma: does every mmHg count? Taiwan J Ophthalmol. 2020;10(4):255\u20138.","journal-title":"Taiwan J Ophthalmol"},{"issue":"10","key":"3566_CR3","doi-asserted-by":"publisher","first-page":"4639","DOI":"10.1007\/s12325-023-02550-w","volume":"40","author":"M Araie","year":"2023","unstructured":"Araie M, Sugiyama K, Aso K, et al. Phase\u00a03 clinical trial comparing the safety and efficacy of netarsudil to ripasudil in patients with primary open-angle glaucoma or ocular hypertension: Japan Rho Kinase Elevated Intraocular Pressure Treatment Trial (J-ROCKET). Adv Ther. 2023;40(10):4639\u201356.","journal-title":"Adv Ther"},{"issue":"4","key":"3566_CR4","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1007\/s12325-020-01277-2","volume":"37","author":"S Asrani","year":"2020","unstructured":"Asrani S, Bacharach J, Holland E, et al. Fixed-dose combination of netarsudil and latanoprost in ocular hypertension and open-angle glaucoma: pooled efficacy\/safety analysis of phase\u00a03 MERCURY-1 and -2. Adv Ther. 2020;37(4):1620\u201331.","journal-title":"Adv Ther"},{"issue":"1","key":"3566_CR5","doi-asserted-by":"publisher","first-page":"P30","DOI":"10.1016\/j.ophtha.2020.10.021","volume":"128","author":"SJ Gedde","year":"2021","unstructured":"Gedde SJ, Chen PP, Muir KW, et al. Primary angle-closure disease Preferred Practice Pattern\u00ae. Ophthalmology. 2021;128(1):P30\u201370.","journal-title":"Ophthalmology"},{"issue":"3","key":"3566_CR6","doi-asserted-by":"publisher","first-page":"e277","DOI":"10.1111\/aos.13568","volume":"96","author":"F Li","year":"2018","unstructured":"Li F, Huang W, Zhang X. Efficacy and safety of different regimens for primary open-angle glaucoma or ocular hypertension: a systematic review and network meta-analysis. Acta Ophthalmol. 2018;96(3):e277\u201384.","journal-title":"Acta Ophthalmol"},{"key":"3566_CR7","unstructured":"RHOPRESSA\u00ae. Highlights of prescribing information. Aerie Pharmaceuticals, Inc. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208254lbl.pdf. Accessed 22 June 2023."},{"key":"3566_CR8","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ajo.2021.01.019","volume":"226","author":"AJ Sit","year":"2021","unstructured":"Sit AJ, Gupta D, Kazemi A, et al. Netarsudil improves trabecular outflow facility in patients with primary open angle glaucoma or ocularhypertension: a phase\u00a02 study. Am J Ophthalmol. 2021;226:262\u20139.","journal-title":"Am J Ophthalmol"},{"key":"3566_CR9","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ajo.2017.11.019","volume":"186","author":"JB Serle","year":"2018","unstructured":"Serle JB, Katz LJ, McLaurin E, et al. Two phase\u00a03 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho kinase elevated IOP treatment trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2018;186:116\u201327.","journal-title":"Am J Ophthalmol"},{"key":"3566_CR10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ajo.2019.03.002","volume":"204","author":"AS Khouri","year":"2019","unstructured":"Khouri AS, Serle JB, Bacharach J, et al. Once-daily netarsudil versus twice-daily timolol in patients with elevated intraocular pressure: the randomized phase\u00a03 ROCKET-4 study. Am J Ophthalmol. 2019;204:97\u2013104.","journal-title":"Am J Ophthalmol"},{"key":"3566_CR11","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ajo.2019.01.003","volume":"200","author":"MY Kahook","year":"2019","unstructured":"Kahook MY, Serle JB, Mah FS, et al. Long-term safety and ocular hypotensive efficacy evaluation of netarsudil ophthalmic solution: Rho kinase elevated IOP treatment trial (ROCKET-2). Am J Ophthalmol. 2019;200:130\u20137.","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"3566_CR12","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ogla.2020.05.008","volume":"3","author":"JW Brubaker","year":"2020","unstructured":"Brubaker JW, Teymoorian S, Lewis RA, et al. One year of netarsudil and latanoprost fixed-dose combination for elevated intraocular pressure: phase\u00a03, randomized MERCURY-1 study. Ophthalmol Glaucoma. 2020;3(5):327\u201338.","journal-title":"Ophthalmol Glaucoma"},{"issue":"5","key":"3566_CR13","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.ogla.2019.03.007","volume":"2","author":"TR Walters","year":"2019","unstructured":"Walters TR, Ahmed IIK, Lewis RA, et al. Once-daily netarsudil\/latanoprost fixed-dose combination for elevated intraocular pressure in the randomized phase\u00a03 MERCURY-2 study. Ophthalmol Glaucoma. 2019;2(5):280\u20139.","journal-title":"Ophthalmol Glaucoma"},{"issue":"1","key":"3566_CR14","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s00417-023-06192-0","volume":"262","author":"I Stalmans","year":"2024","unstructured":"Stalmans I, Lim KS, Oddone F, et al. MERCURY-3: a randomized comparison of netarsudil\/latanoprost and bimatoprost\/timolol in open-angle glaucoma and ocular hypertension. Graefes Arch Clin Exp Ophthalmol. 2024;262(1):179\u201390.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"3566_CR15","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1111\/aos.12829","volume":"94","author":"H Tanihara","year":"2016","unstructured":"Tanihara H, Inoue T, Yamamoto T, et al. One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension. Acta Ophthalmol. 2016;94(1):e26-34.","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"3566_CR16","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10384-022-00970-9","volume":"67","author":"Y Kiuchi","year":"2023","unstructured":"Kiuchi Y, Inoue T, Shoji N, et al. The Japan Glaucoma Society guidelines for glaucoma 5th edition. Jpn J Ophthalmol. 2023;67(2):189\u2013254.","journal-title":"Jpn J Ophthalmol"},{"issue":"2","key":"3566_CR17","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/14740338.2024.2436062","volume":"24","author":"G Hollo","year":"2025","unstructured":"Hollo G. Ocular hyperemia associated with topical glaucoma medication: understanding and differentiating clinical appearance and underlying mechanisms. Expert Opin Drug Saf. 2025;24(2):145\u201356.","journal-title":"Expert Opin Drug Saf"},{"issue":"9","key":"3566_CR18","first-page":"6125","volume":"59","author":"C-W Lin","year":"2018","unstructured":"Lin C-W, Foley BE, Carbajal K, Kopczynski C. Evaluation of the potential of AR-13324 and AR-13503 to induce phospholipidosis. Invest Ophthalmol Vis Sci. 2018;59(9):6125.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"3566_CR19","doi-asserted-by":"publisher","DOI":"10.7326\/L22-0490","volume":"176","author":"LM DeTora","year":"2023","unstructured":"DeTora LM, Lane T, Sykes A, DiBiasi F, Toroser D, Citrome L. Good publication practice (GPP) guidelines for company-sponsored biomedical research: 2022 update. Ann Intern Med. 2023;176(3):eL220490.","journal-title":"Ann Intern Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03566-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03566-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03566-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T04:51:52Z","timestamp":1780116712000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03566-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["3566"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03566-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"8 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Makoto Aihara is a consultant and\/or has received grant support or honoraria from Santen Pharmaceutical Co., Ltd., Alcon Japan, Pfizer, Otsuka Pharmaceutical Co., Ltd., CREWT Medical Systems, Rohto Nitten Co., Ltd., Sato Pharmaceutical Co., Ltd., Carl Zeiss, Kowa Pharmaceutical Co., Ltd., HOYA, Allergan, Johnson & Johnson, Wakamoto Pharmaceutical Co., Ltd., Novartis, Glaukos, TOMEY and TOPCON.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in compliance with institutional review boards (IRBs) and the Good Clinical Practice for Drugs guidelines, and in accordance with the Declaration of Helsinki. IRBs included Shintokai Medical Corporation, Shin-Akasaka, Jinbo Orthopedics and the Society for the Ethics of Clinical Research. Further details are presented in Table\u00a0\n                      \n                      . Ethical approval ID numbers are unavailable due to the location of the IRBs. All participants provided consent before the study commenced.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Medical writing support, including assisting the author with development of the outline and initial draft and incorporation of comments was provided by Abbie Rodger, BSc, editorial support, including fact checking, referencing, figure preparation, formatting, proofreading and submission was provided by Isobel Markham, MSc, and Jess Fawcett, BSc, of the Prime Group of Companies (Knutsford, UK); this support was funded by Santen Pharmaceuticals Co., Inc., according to Good Publication Practice guidelines [\n                      \n                      ].","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Medical Writing\/Editorial Assistance"}}]}}